LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 229

Search options

  1. Article: Autoimmune Polyendocrine Syndromes in Adult Italian Celiac Disease Patients.

    Pallotta, Dante Pio / Granito, Alessandro / Raiteri, Alberto / Boe, Maria / Pratelli, Agnese / Giamperoli, Alice / Monaco, Giovanni / Faggiano, Chiara / Tovoli, Francesco

    Journal of clinical medicine

    2024  Volume 13, Issue 2

    Abstract: Celiac disease (CD) is frequently associated with other autoimmune disorders. Different studies have explored the association between CD and single autoimmune endocrine disease (AED), especially autoimmune thyroiditis (AIT) and type-1 diabetes mellitus ( ... ...

    Abstract Celiac disease (CD) is frequently associated with other autoimmune disorders. Different studies have explored the association between CD and single autoimmune endocrine disease (AED), especially autoimmune thyroiditis (AIT) and type-1 diabetes mellitus (T1DM). Data about CD as a component of autoimmune polyendocrine syndrome (APS) are scant. We analyzed a large dataset including prospectively collected data from 920 consecutive adult CD patients diagnosed in a third-level Italian institution in the 2013-2023 period, The prevalence of isolated autoimmune endocrine diseases and APS were collected. A total of 262 (28.5%) CD patients had at least one associated AED, with AIT (n = 223, 24.2%) and T1DM (n = 27, 2.9%) being the most frequent conditions. In most cases (n = 173, 66%), AEDs were diagnosed after CD. Thirteen patients (1.4%) had at least two of the requested three endocrinopathies, satisfying the diagnosis of type 2 APS. APS-2 is a rare but not exceptional occurrence among Italian CD patients, underscoring the intricate and multifaceted nature of autoimmune disorders. Periodic evaluations of thyroid function and glycaemia should be recommended after the diagnosis of CD together with testing for autoantibodies that may be helpful in assessing disease risk before disease onset. Likewise, implementation of a systematic screening for CD amongst T1DM and other autoimmune endocrine diseases are paramount.
    Language English
    Publishing date 2024-01-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13020488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Anti-ganglioside antibodies and celiac disease.

    Granito, Alessandro / Tovoli, Francesco / Raiteri, Alberto / Volta, Umberto

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

    2021  Volume 17, Issue 1, Page(s) 53

    Language English
    Publishing date 2021-05-28
    Publishing country England
    Document type Letter
    ZDB-ID 2434973-2
    ISSN 1710-1492 ; 1710-1484
    ISSN (online) 1710-1492
    ISSN 1710-1484
    DOI 10.1186/s13223-021-00557-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Tocilizumab: From Rheumatic Diseases to COVID-19.

    Raiteri, Alberto / Piscaglia, Fabio / Granito, Alessandro / Tovoli, Francesco

    Current pharmaceutical design

    2021  Volume 27, Issue 13, Page(s) 1597–1607

    Abstract: Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment ...

    Abstract Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment for severe coronavirus-induced disease 2019 (COVID-19). Despite the lack of direct antiviral effects, tocilizumab could reduce the immune-induced organ damage caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infection. Until recently, most reports on tocilizumab for COVID-19 included a limited number of patients, preventing an overall evaluation of its efficacy and safety for this specific condition. Therefore, we reviewed the literature regarding the physiopathological rationale of tocilizumab for COVID-19 and its outcomes. We searched the MEDLINE database with the string "(SARS-CoV-2 OR coronavirus OR COVID-19 OR MERS- cov OR SARS-cov) AND (IL-6 OR interleukin 6 OR tocilizumab)". While the scientific rationale supporting tocilizumab for COVID-19 is solid, the evidence regarding the outcomes remains controversial. Available data and results from ongoing trials will provide useful information in the event of new COVID-19 outbreaks or future pandemics from different coronaviruses.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; COVID-19/drug therapy ; Humans ; RNA, Viral ; Rheumatic Diseases ; SARS-CoV-2
    Chemical Substances Antibodies, Monoclonal, Humanized ; RNA, Viral ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2021-03-15
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 1304236-1
    ISSN 1873-4286 ; 1381-6128
    ISSN (online) 1873-4286
    ISSN 1381-6128
    DOI 10.2174/1381612827666210311141512
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: COVID-19: Has the Liver Been Spared?

    Brandi, Nicolò / Spinelli, Daniele / Granito, Alessandro / Tovoli, Francesco / Piscaglia, Fabio / Golfieri, Rita / Renzulli, Matteo

    International journal of molecular sciences

    2023  Volume 24, Issue 2

    Abstract: The liver is a secondary and often collateral target of COVID-19 disease but can lead to important consequences. COVID-19 might directly cause a high number of complications in patients with pre-existing chronic liver disease, increasing their risk of ... ...

    Abstract The liver is a secondary and often collateral target of COVID-19 disease but can lead to important consequences. COVID-19 might directly cause a high number of complications in patients with pre-existing chronic liver disease, increasing their risk of hepatic decompensation. Moreover, it also determines indirect consequences in the management of patients with liver disease, especially in those suffering from decompensated cirrhosis and HCC, as well as in the execution of their follow-up and the availability of all therapeutic possibilities. Liver imaging in COVID-19 patients proved to be highly nonspecific, but it can still be useful for identifying the complications that derive from the infection. Moreover, the recent implementation of telemedicine constitutes a possible solution to both the physical distancing and the re-organizational difficulties arising from the pandemic. The present review aims to encompass the currently hypothesized pathophysiological mechanisms of liver injury in patients with COVID-19 mediated by both the direct invasion of the virus and its indirect effects and analyze the consequence of the pandemic in patients with chronic liver disease and liver tumors, with particular regard to the management strategies that have been implemented to face this worldwide emergency and that can be further improved.
    MeSH term(s) Humans ; Liver Neoplasms/epidemiology ; Liver Neoplasms/etiology ; Liver Neoplasms/therapy ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/therapy ; COVID-19/complications ; Liver Cirrhosis/etiology
    Language English
    Publishing date 2023-01-06
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24021091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: TKIs in combination with immunotherapy for hepatocellular carcinoma.

    Stefanini, Bernardo / Ielasi, Luca / Chen, Rusi / Abbati, Chiara / Tonnini, Matteo / Tovoli, Francesco / Granito, Alessandro

    Expert review of anticancer therapy

    2023  Volume 23, Issue 3, Page(s) 279–291

    Abstract: Introduction: The treatment landscape of hepatocellular carcinoma (HCC) has significantly changed over the last 5 years with multiple options in the frontline, second line, and beyond. Tyrosine kinase inhibitors (TKIs) were the first approved systemic ... ...

    Abstract Introduction: The treatment landscape of hepatocellular carcinoma (HCC) has significantly changed over the last 5 years with multiple options in the frontline, second line, and beyond. Tyrosine kinase inhibitors (TKIs) were the first approved systemic treatments for the advanced stage of HCC; however, thanks to the increasing knowledge and characterization of the immunological features of the tumor microenvironment, the systemic treatment of HCC has been further expanded with the immune checkpoint inhibitor (ICI) approach and the following evidence of the higher efficacy obtained with combined treatment with atezolizumab plus bevacizumab over sorafenib.
    Areas covered: In this review, we look at rationale, efficacy, and safety profiles of current and emerging ICI/TKI combination treatments and discuss the available results from other clinical trials using similar combinatorial therapeutic approaches.
    Expert opinion: Angiogenesis and immune evasion are the two key pathogenic hallmarks of HCC. While the pioneering regimen of atezolizumab/bevacizumab is consolidating as the first-line treatment of advanced HCC, it will be essential, in the near future, to determine the best second-line treatment options and how to optimize the selection of the most effective therapies. These points still need to be addressed by future studies that are largely warranted to enhance the treatment's effectiveness and ultimately to tackle down HCC lethality.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Bevacizumab ; Liver Neoplasms/drug therapy ; Immunotherapy ; Sorafenib ; Tumor Microenvironment
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Sorafenib (9ZOQ3TZI87)
    Language English
    Publishing date 2023-02-26
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2023.2181162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Autoantibodies to speckled protein family in primary biliary cholangitis.

    Granito, Alessandro / Muratori, Luigi / Tovoli, Francesco / Muratori, Paolo

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

    2021  Volume 17, Issue 1, Page(s) 35

    Abstract: The autoantibody profile of primary biliary cholangitis (PBC) includes antinuclear antibodies (ANA) which are detectable by indirect immunofluorescence in more than 50% of PBC patients. One of the two immunofluorescence patterns which are historically ... ...

    Abstract The autoantibody profile of primary biliary cholangitis (PBC) includes antinuclear antibodies (ANA) which are detectable by indirect immunofluorescence in more than 50% of PBC patients. One of the two immunofluorescence patterns which are historically considered "PBC-specific" is the so-called "multiple nuclear dots" (MND) targeting nuclear body proteins such as Sp100, Sp140, Sp140L proteins, promyelocytic leukemia protein (PML) and small ubiquitin-related modifier proteins (SUMO). It has been hypothesized a role of nuclear body protein alterations in immune disorders such as PBC, thus suggesting novel and more refined therapeutic approaches.
    Language English
    Publishing date 2021-03-31
    Publishing country England
    Document type Letter
    ZDB-ID 2434973-2
    ISSN 1710-1492 ; 1710-1484
    ISSN (online) 1710-1492
    ISSN 1710-1484
    DOI 10.1186/s13223-021-00539-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Antinuclear antibodies in COVID 19.

    Muratori, Paolo / Lenzi, Marco / Muratori, Luigi / Granito, Alessandro

    Clinical and translational science

    2021  Volume 14, Issue 5, Page(s) 1627–1628

    MeSH term(s) Antibodies, Antinuclear ; COVID-19 ; Humans ; SARS-CoV-2
    Chemical Substances Antibodies, Antinuclear
    Language English
    Publishing date 2021-05-01
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2433157-0
    ISSN 1752-8062 ; 1752-8054
    ISSN (online) 1752-8062
    ISSN 1752-8054
    DOI 10.1111/cts.13026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting.

    Granito, Alessandro / Muratori, Paolo / Tovoli, Francesco / Muratori, Luigi

    Autoimmunity reviews

    2021  Volume 20, Issue 4, Page(s) 102787

    MeSH term(s) Antibodies, Antineutrophil Cytoplasmic ; Autoantibodies ; Autoimmune Diseases/diagnosis ; Cytoplasm ; Humans ; Laboratories ; Neutrophils
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic ; Autoantibodies
    Language English
    Publishing date 2021-02-18
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2144145-5
    ISSN 1873-0183 ; 1568-9972
    ISSN (online) 1873-0183
    ISSN 1568-9972
    DOI 10.1016/j.autrev.2021.102787
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset.

    Muratori, Paolo / Granito, Alessandro / Lenzi, Marco / Muratori, Luigi

    Liver international : official journal of the International Association for the Study of the Liver

    2021  Volume 41, Issue 3, Page(s) 529–534

    Abstract: Autoimmune Hepatitis (AIH) is a chronic inflammatory liver disease of unknown aetiology characterized by the presence of autoantibodies, hypergammaglobulinaemia with specific IgG increase and interface hepatitis on liver histology. The clinical course of ...

    Abstract Autoimmune Hepatitis (AIH) is a chronic inflammatory liver disease of unknown aetiology characterized by the presence of autoantibodies, hypergammaglobulinaemia with specific IgG increase and interface hepatitis on liver histology. The clinical course of AIH is classically characterized by fluctuating periods of decreased or increased disease activity and therefore its clinical spectrum is variable ranging from no symptoms to severe acute hepatitis and even fulminant hepatic failure. Acute presentation may not differ from acute hepatitis of other causes and diagnosis can be difficult. We describe our experience on diagnostic performance of the two AIH scoring systems in acute onset of AIH and found that revised version of the original criteria (1999) achieves the diagnosis in about 30% of patients who presented with normal IgG serum levels and lower frequency of autoantibody positivity in whom the simplified score did not allow the diagnosis.
    MeSH term(s) Acute Disease ; Autoantibodies ; Hepatitis, Autoimmune/diagnosis ; Humans
    Chemical Substances Autoantibodies
    Language English
    Publishing date 2021-01-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2102783-3
    ISSN 1478-3231 ; 1478-3223
    ISSN (online) 1478-3231
    ISSN 1478-3223
    DOI 10.1111/liv.14778
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis.

    Granito, Alessandro / Muratori, Paolo / Muratori, Luigi

    Journal of hepatology

    2021  Volume 75, Issue 6, Page(s) 1503–1505

    MeSH term(s) Acute-On-Chronic Liver Failure/diagnosis ; Acute-On-Chronic Liver Failure/etiology ; Hepatitis B virus ; Hepatitis, Autoimmune/complications ; Hepatitis, Autoimmune/diagnosis ; Humans ; Liver Cirrhosis
    Language English
    Publishing date 2021-07-03
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2021.06.035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top